Substipharm Overview
- Year Founded
-
1995
- Status
-
Private
- Employees
-
150
- Latest Deal Type
-
Debt
Substipharm General Information
Description
Developer, manufacturer, and distributor of generic, niche, and mature pharmaceuticals intended to provide more affordable healthcare and to improve access to medicines. The company offers a wide range of pharmaceutical products and dossiers including over-the-counter pharmaceuticals, food, and dietary supplements, and prescription brands, thereby enabling clients with products that cover almost all core therapeutic areas.
Contact Information
Website
www.substipharm.comCorporate Office
- 24 rue Erlanger
- 75016 Paris
- France
Corporate Office
- 24 rue Erlanger
- 75016 Paris
- France
Substipharm Timeline
Substipharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Debt - General | Completed | Generating Revenue | ||||
| 2. Debt - Acquisition | 09-Sep-2025 | Completed | Generating Revenue | |||
| 1. Debt - General | 15-Oct-2024 | $388M | $388M | Completed | Generating Revenue |
Substipharm Patents
Substipharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4062907-A1 | Formulation for oral administration of ivermectin and uses thereof | Inactive | 23-Mar-2021 | ||
| EP-4313155-A1 | Oral formulation of ivermectin and uses thereof | Pending | 23-Mar-2021 | ||
| WO-2022200402-A1 | Oral formulation of ivermectin and uses thereof | Inactive | 23-Mar-2021 | ||
| ES-2978020-T3 | A pharmaceutical composition comprising racecadotril and a method of preparing the same | Active | 06-Mar-2017 | ||
| EP-3592333-A1 | A pharmaceutical composition comprising racecadotril and process for preparing the same | Active | 06-Mar-2017 | A61K31/216 |
Substipharm Signals
Substipharm Investments & Acquisitions (6)
Substipharm’s most recent deal was a Corporate Asset Purchase with Opella (Aspégic). The deal was made on 31-Oct-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Opella (Aspégic) | 31-Oct-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Sanofi (Kardégic) | 31-Oct-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Vectans Pharma | 01-Jul-2025 | Merger/Acquisition | Drug Delivery | ||
| IMOJEV | 30-Nov-2022 | Corporate Asset Purchase | Buildings and Property | ||
| Speciality European Pharma (Mitem) | 27-Apr-2017 | Corporate Asset Purchase | Buildings and Property |
Substipharm Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Indigo Therapeutics | Paris, France | 2015 |
Substipharm FAQs
-
When was Substipharm founded?
Substipharm was founded in 1995.
-
Where is Substipharm headquartered?
Substipharm is headquartered in Paris, France.
-
What is the size of Substipharm?
Substipharm has 150 total employees.
-
What industry is Substipharm in?
Substipharm’s primary industry is Pharmaceuticals.
-
Is Substipharm a private or public company?
Substipharm is a Private company.
-
What is Substipharm’s current revenue?
The current revenue for Substipharm is .
-
How much funding has Substipharm raised over time?
Substipharm has raised $388M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process